Sort
48,018 grants matching “immunotherapy”
Hes1-loss promotes dysregulation of epithelial homeostasis and inflammation in a serrated adenocarcinoma model
$415,163Lan Zhou · Case Western Reserve University · R01 · FY2020 · CA
Hes1-loss promotes dysregulation of epithelial homeostasis and inflammation in a serrated adenocarcinoma model
$415,163Lan Zhou · Case Western Reserve University · R01 · FY2021 · CA
Harnessing artificial microRNA clusters against glioblastoma epigenetic plasticity and resistance to therapy
$415,160Pier Paolo Peruzzi · Brigham And Women'S Hospital · R01 · FY2020 · NS
Harnessing artificial microRNA clusters against glioblastoma epigenetic plasticity and resistance to therapy
$415,160Pier Paolo Peruzzi · Brigham And Women'S Hospital · R01 · FY2021 · NS
Harnessing artificial microRNA clusters against glioblastoma epigenetic plasticity and resistance to therapy
$415,160Pier Paolo Peruzzi · Brigham And Women'S Hospital · R01 · FY2022 · NS
Harnessing Artificial MicroRNA Clusters Against Glioblastoma Epigenetic Plasticity and Resistance to Therapy
$415,160Pier Paolo Peruzzi · Brigham And Women'S Hospital · R01 · FY2025 · NS
Harnessing Artificial MicroRNA Clusters Against Glioblastoma Epigenetic Plasticity and Resistance to Therapy
$415,160Pier Paolo Peruzzi · Brigham And Women'S Hospital · R01 · FY2023 · NS
Project 3: Chronic interferon and bile acid signaling as drivers of immunosuppression in age-related liver cancer
$415,068Susan M Kaech · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2022 · AG
SOUTHWEST ONCOLOGY GROUP CA-13612
$415,058University Of Arizona · U10 · FY2000 · CA
Project 1 Targeting the PI3K Pathway to Overcome Resistance to Immunotherapy in Melanomas with Loss of PTEN
$415,046Michael Davies · University Of Tx Md Anderson Can Ctr · P50 · FY2022 · CA
Project 1 Targeting the PI3K Pathway to Overcome Resistance to Immunotherapy in Melanomas with Loss of PTEN
$415,045Michael Davies · University Of Tx Md Anderson Can Ctr · P50 · FY2019 · CA
Transplanting Unique Human Microbiomes to Improve Immunotherapy in Glioblastoma
$415,031Braden Cox McFarland · University Of Alabama At Birmingham · R21 · FY2021 · CA
Sensitization to RIPK1-dependent death as a strategy to enhance response of renal cell carcinoma (RCC) to immunotherapy
$415,000Adrian T Ting · Mayo Clinic Rochester · R21 · FY2023 · CA
Targeting Viral Envelope Glycoproteins with Synthetic Antibodies
$415,000Jonathan R. Lai · Albert Einstein College Of Medicine · R01 · FY2010 · AI
Binding and Presentation of Lipid Antigens by CD1
$415,000Steven A Porcelli · Albert Einstein College Of Medicine · R01 · FY2009 · AI
Inflammasomes - a driver of sexual dimorphism to glioma therapies
$414,953Vidyalakshmi Chandramohan · Duke University · R01 · FY2025 · NS
Quantitative Lung Function Imaging to Reduce Toxicity for patients treated with Radiation and Immunotherapy
$414,944Yevgeniy Vinogradskiy · Thomas Jefferson University · UH3 · FY2023 · CA
Pathogenesis of Postoperative Cognitive Dysfunction
$414,912Zhongcong Xie · Massachusetts General Hospital · R01 · FY2014 · AG
Role of Antigen Glycosylation in Mucin Binding by Monoclonal Antibodies
$414,854Cory Brooks · California State University Fresno · R15 · FY2020 · CA
Impact of Genetic Diversity on Human Xenograft Tumor Growth
$414,834Muneer Gulamhusein Hasham · Jackson Laboratory · R33 · FY2022 · CA
Directed evolution of TCRs with improved antigen sensitivity
$414,803Michael Birnbaum · Massachusetts Institute Of Technology · R21 · FY2025 · CA
ANTIBODY-TARGETED IMMUNOTHERAPY OF CANCER
$414,783Fox Chase Cancer Center · R01 · FY2002 · CA
CAREER DEVELOPMENT IN PEDIATRIC AND MEDICAL ONCOLOGY
$414,780Fred Hutchinson Cancer Research Center · K12 · FY2000 · CA
Investigating and modeling MYD88L265P and co-occurring mutations in mature B-cell malignancies
$414,729Ruben D Carrasco · Dana-Farber Cancer Inst · R01 · FY2025 · CA
Neuroimmunology of Malignant Brain Tumors: Innate Mechanisms
$414,676Pedro R Lowenstein · University Of Michigan At Ann Arbor · R01 · FY2020 · NS